Early clinical experience with imatinib in COVID-19: Searching for a dual effect.

Autor: Morales-Ortega A; Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain. Electronic address: alejandro.morales@salud.madrid.org., Rivas-Prado L; Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain., Frutos-Pérez B; Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain., Jaenes-Barrios B; Primary Health Care Center Castilla La Nueva, Fuenlabrada, Madrid, Spain., Farfán-Sedano AI; Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain., García-Parra CJ; Department of Emergency Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain., Hernández-Muniesa B; Department of Hospital Pharmacy, Hospital Universitario de Fuenlabrada, Madrid, Spain., Duarte-Millán MÁ; Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain., Madroñal-Cerezo E; Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain., Ontañón-Nasarre A; Department of Hospital Pharmacy, Hospital Universitario de Fuenlabrada, Madrid, Spain., Ruiz-Giardín JM; Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain., Bermejo F; Department of Gastroenterology, Hospital Universitario de Fuenlabrada. Instituto de Investigación, Sanitaria Hospital La Paz (IdiPAZ), Madrid, Spain., García-Gil M; Department of Hospital Pharmacy, Hospital Universitario de Fuenlabrada, Madrid, Spain., Gonzalo-Pascua S; Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain., San Martín-López JV; Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain., Bernal-Bello D; Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.
Jazyk: angličtina
Zdroj: The Journal of infection [J Infect] 2021 May; Vol. 82 (5), pp. 186-230. Date of Electronic Publication: 2021 Feb 05.
DOI: 10.1016/j.jinf.2021.02.002
Abstrakt: Competing Interests: Declaration of Competing Interests David Bernal-Bello is the principal investigator of a non-sponsored randomised trial investigating the therapeutic role of imatinib and baricitinib in COVID-19 patients (NCT04346147). The rest of the authors are sub-investigators in this project. All authors declare no other competing interests.
Databáze: MEDLINE
Externí odkaz: